What was studied?
The randomized, double-blind, placebo-controlled study enrolled 201 adolescents, almost all with obesity. The primary analysis examined the percentage change in body-mass index over 68 weeks alongside a lifestyle intervention.
What did the researchers report?
The semaglutide study group had a greater reduction in BMI than placebo. The trial used age-appropriate eligibility and outcome definitions and assessed adverse events during a defined monitoring period.
What are the limits?
BMI change in growing adolescents differs from an adult weight endpoint. Long-term developmental and safety questions cannot be settled by this follow-up alone. This summary provides research context and is not a recommendation for minors or evidence supporting any personal use of catalog materials.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.